David Kobulnicky, MD
Hematology & Oncology · Hampton, VANPI 1245676477
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.8%), other and speaking fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Novartis at 39.4% of the total. That places this record below the midpoint for hematology & oncology clinicians in VA, where the typical reported total is $1,232.
Across 18 payments — averaging $51.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$365
- Array Biopharma Inc$150
- Blueprint Medicines Corporation$120
- Astellas Pharma US Inc$91
- Adaptive Biotechnologies Corporation$64
- AVEO Pharmaceuticals, Inc.$25
- plus $111 from 6 others
Across 7 payments — averaging $30,616 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$140K
- E.r. Squibb & Sons, L.L.C.$74K
What the payments were for
- Speaking & faculty fees$15016%
- Food & beverage$34137%
- Education$13515%
- Other$29932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $365 |
| Array Biopharma Inc | 1 | $150 |
| Blueprint Medicines Corporation | 1 | $120 |
| Astellas Pharma US Inc | 1 | $91 |
| Adaptive Biotechnologies Corporation | 1 | $64 |
| AVEO Pharmaceuticals, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $19 |
| Bayer | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$925 in reported general payments places this provider in the 45th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 57 | $788,926 |
| JakafiRuxolitinib Phosphate | 32 | $538,638 |
| VonjoPacritinib Citrate | 20 | $535,721 |
| CalquenceAcalabrutinib Maleate | 32 | $468,652 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $341,600 |
| Lenalidomide | 22 | $299,716 |
| TagrissoOsimertinib Mesylate | 17 | $281,333 |
| ScemblixAsciminib Hydrochloride | 12 | $244,931 |
| RevlimidLenalidomide | 16 | $210,831 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $167,853 |
| TafinlarDabrafenib Mesylate | 12 | $154,599 |
| PromactaEltrombopag Olamine | 12 | $115,563 |
| EliquisApixaban | 79 | $67,384 |
| XareltoRivaroxaban | 39 | $38,186 |
| VenclextaVenetoclax | 12 | $37,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisScemblix, Mekinist, Tafinlar, Promacta | $365 | $682,94648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Hampton
- Ruby KochharHampton$236K
- Mark FlemingHampton$71K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.